| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Katja Hochgräfe, Astrid Sydow, Eva-Maria Mandelko. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology. The FEBS journal. vol 280. issue 18. 2013-10-25. PMID:23517246. |
accumulation of amyloidogenic proteins such as tau is a hallmark of neurodegenerative diseases including alzheimer disease and fronto-temporal dementias. |
2013-10-25 |
2023-08-12 |
mouse |
| Eva Bentmann, Christian Haass, Dorothee Dorman. Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma. The FEBS journal. vol 280. issue 18. 2013-10-25. PMID:23587065. |
tau inclusions in alzheimer's disease) show a co-localization with t cell internal antigen-1 as well. |
2013-10-25 |
2023-08-12 |
Not clear |
| Huilai Tian, Eliot Davidowitz, Patricia Lopez, Sharareh Emadi, James Moe, Michael Sierk. Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. International journal of cell biology. vol 2013. 2013-10-25. PMID:24159335. |
in alzheimer's disease (ad), tau aggregates into fibrils and higher order neurofibrillary tangles, a key histopathological feature of ad. |
2013-10-25 |
2023-08-12 |
human |
| David J Irwin, Todd J Cohen, Murray Grossman, Steven E Arnold, Elisabeth McCarty-Wood, Vivianna M Van Deerlin, Virginia M-Y Lee, John Q Trojanowsk. Acetylated tau neuropathology in sporadic and hereditary tauopathies. The American journal of pathology. vol 183. issue 2. 2013-10-24. PMID:23885714. |
we have recently shown acetylation of tau at lysine residue 280 (ac-k280) to be a disease-specific modification in alzheimer disease (ad), corticobasal degeneration, and progressive supranuclear palsy, likely representing a major regulatory tau modification. |
2013-10-24 |
2023-08-12 |
Not clear |
| C Tackenberg, S Grinschgl, A Trutzel, A C Santuccione, M C Frey, U Konietzko, J Grimm, R Brandt, R M Nitsc. NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell death & disease. vol 4. 2013-10-23. PMID:23618906. |
aggregates of amyloid-beta (aβ) and tau are hallmarks of alzheimer's disease (ad) leading to neurodegeneration and synaptic loss. |
2013-10-23 |
2023-08-12 |
mouse |
| Manuela Polydoro, Alix de Calignon, Marc Suárez-Calvet, Laura Sanchez, Kevin R Kay, Samantha B Nicholls, Allyson D Roe, Rose Pitstick, George A Carlson, Teresa Gómez-Isla, Tara L Spires-Jones, Bradley T Hyma. Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 33. issue 33. 2013-10-23. PMID:23946388. |
neurofibrillary tangles (nfts), a marker of neuronal alterations in alzheimer's disease (ad) and other tauopathies, are comprised of aggregates of hyperphosphorylated tau protein. |
2013-10-23 |
2023-08-12 |
mouse |
| Wesley Jongbloed, Maartje I Kester, Wiesje M van der Flier, Robert Veerhuis, Philip Scheltens, Marinus A Blankenstein, Charlotte E Teunisse. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 9. issue 3. 2013-10-22. PMID:23110867. |
multiplex assays such as xmap have been proposed for the assessment of alzheimer's disease (ad) biomarkers amyloid β 42 (aβ42), tau (tau), and phosphorylated tau (ptau) in cerebrospinal fluid (csf). |
2013-10-22 |
2023-08-12 |
human |
| Caroline Smet-Nocca, Hélène Launay, Jean-Michel Wieruszeski, Guy Lippens, Isabelle Landrie. Unraveling a phosphorylation event in a folded protein by NMR spectroscopy: phosphorylation of the Pin1 WW domain by PKA. Journal of biomolecular NMR. vol 55. issue 4. 2013-10-22. PMID:23456038. |
the pin1 protein plays a critical role in the functional regulation of the hyperphosphorylated neuronal tau protein in alzheimer's disease and is by itself regulated by phosphorylation. |
2013-10-22 |
2023-08-12 |
Not clear |
| Lyzel S Elias-Sonnenschein, Seppo Helisalmi, Teemu Natunen, Anette Hall, Teemu Paajanen, Sanna-Kaisa Herukka, Marjo Laitinen, Anne M Remes, Anne M Koivisto, Kari M Mattila, Terho Lehtimäki, Frans R J Verhey, Pieter Jelle Visser, Hilkka Soininen, Mikko Hiltune. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort. PloS one. vol 8. issue 4. 2013-10-22. PMID:23573206. |
to understand the relation between risk genes for alzheimer's disease (ad) and their influence on biomarkers for ad, we examined the association of ad in the finnish cohort with single nucleotide polymorphisms (snps) from top alzgene loci, genome-wide association studies (gwas), and candidate gene studies; and tested the correlation between these snps and ad markers aβ(1-42), total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (csf). |
2013-10-22 |
2023-08-12 |
Not clear |
| Niklas Mattsson, Ulf Andreasson, Staffan Persson, Maria C Carrillo, Steven Collins, Sonia Chalbot, Neal Cutler, Diane Dufour-Rainfray, Anne M Fagan, Niels H H Heegaard, Ging-Yuek Robin Hsiung, Bradley Hyman, Khalid Iqbal, Stephan A Kaeser, Stephan A Käser, D Richard Lachno, Alberto Lleó, Piotr Lewczuk, José L Molinuevo, Piero Parchi, Axel Regeniter, Robert A Rissman, Robert Rissman, Hanna Rosenmann, Giuseppe Sancesario, Johannes Schröder, Leslie M Shaw, Charlotte E Teunissen, John Q Trojanowski, Hugo Vanderstichele, Manu Vandijck, Marcel M Verbeek, Henrik Zetterberg, Kaj Blenno. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 9. issue 3. 2013-10-22. PMID:23622690. |
the cerebrospinal fluid (csf) biomarkers amyloid beta 1-42, total tau, and phosphorylated tau are used increasingly for alzheimer's disease (ad) research and patient management. |
2013-10-22 |
2023-08-12 |
Not clear |
| Chad J Leugers, Ju Yong Koh, Willis Hong, Gloria Le. Tau in MAPK activation. Frontiers in neurology. vol 4. 2013-10-22. PMID:24146661. |
the nature of "toxic" tau in alzheimer's disease (ad) has been unclear. |
2013-10-22 |
2023-08-12 |
Not clear |
| Julien Dumurgier, Olivier Vercruysse, Claire Paquet, Stéphanie Bombois, Chloé Chaulet, Jean-Louis Laplanche, Katell Peoc'h, Susanna Schraen, Florence Pasquier, Jacques Touchon, Jacques Hugon, Sylvain Lehmann, Audrey Gabell. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 9. issue 4. 2013-10-21. PMID:23141384. |
the assessment of total tau, phosphorylated tau (ptau-181) and amyloid beta (aβ 1-42) concentrations in the cerebrospinal fluid (csf) of subjects has been validated for the diagnosis of alzheimer's disease (ad). |
2013-10-21 |
2023-08-12 |
human |
| Ling Li, Zhirong Liu, Juanfang Liu, Xuhui Tai, Xinghua Hu, Xuedong Liu, Zhongliang Wu, Guangyun Zhang, Ming Shi, Gang Zha. Ginsenoside Rd attenuates beta-amyloid-induced tau phosphorylation by altering the functional balance of glycogen synthase kinase 3beta and protein phosphatase 2A. Neurobiology of disease. vol 54. 2013-10-21. PMID:23321003. |
neurofibrillary tangles are aggregates of hyperphosphorylated tau that are one of the pathological hallmarks of alzheimer's disease (ad). |
2013-10-21 |
2023-08-12 |
mouse |
| Nobuyuki Okamura, Shozo Furumoto, Ryuichi Harada, Tetsuro Tago, Takeo Yoshikawa, Michelle Fodero-Tavoletti, Rachel S Mulligan, Victor L Villemagne, Hiroyasu Akatsu, Takayuki Yamamoto, Hiroyuki Arai, Ren Iwata, Kazuhiko Yanai, Yukitsuka Kud. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 54. issue 8. 2013-10-21. PMID:23857514. |
novel 18f-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in alzheimer disease. |
2013-10-21 |
2023-08-12 |
Not clear |
| Nobuyuki Okamura, Shozo Furumoto, Ryuichi Harada, Tetsuro Tago, Takeo Yoshikawa, Michelle Fodero-Tavoletti, Rachel S Mulligan, Victor L Villemagne, Hiroyasu Akatsu, Takayuki Yamamoto, Hiroyuki Arai, Ren Iwata, Kazuhiko Yanai, Yukitsuka Kud. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 54. issue 8. 2013-10-21. PMID:23857514. |
neurofibrillary tangles in alzheimer disease (ad) brains are composed of the microtubule-associated protein tau. |
2013-10-21 |
2023-08-12 |
Not clear |
| Jasmine Ramcharitar, Steffen Albrecht, Veronica M Afonso, Vikas Kaushal, David A Bennett, Andrea C Leblan. Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer disease. Journal of neuropathology and experimental neurology. vol 72. issue 9. 2013-10-21. PMID:23965742. |
cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and alzheimer disease. |
2013-10-21 |
2023-08-12 |
Not clear |
| Mark A Greenough, James Camakaris, Ashley I Bus. Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochemistry international. vol 62. issue 5. 2013-10-17. PMID:22982299. |
alzheimer's disease is the leading cause of dementia in the elderly and is defined by two pathological hallmarks; the accumulation of aggregated amyloid beta and excessively phosphorylated tau proteins. |
2013-10-17 |
2023-08-12 |
Not clear |
| Seán T O'Dowd, Mustafa T Ardah, Per Johansson, Aleksey Lomakin, George B Benedek, Kinley A Roberts, Gemma Cummins, Omar M El Agnaf, Johan Svensson, Henrik Zetterberg, Timothy Lynch, Dominic M Wals. The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. Journal of Alzheimer's disease : JAD. vol 33. issue 4. 2013-10-17. PMID:23034520. |
the elisa-measured increase in cerebrospinal fluid tau that discriminates alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. |
2013-10-17 |
2023-08-12 |
Not clear |
| Seán T O'Dowd, Mustafa T Ardah, Per Johansson, Aleksey Lomakin, George B Benedek, Kinley A Roberts, Gemma Cummins, Omar M El Agnaf, Johan Svensson, Henrik Zetterberg, Timothy Lynch, Dominic M Wals. The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. Journal of Alzheimer's disease : JAD. vol 33. issue 4. 2013-10-17. PMID:23034520. |
elevated cerebrospinal fluid concentrations of tau discriminate alzheimer's disease from other neurodegenerative conditions. |
2013-10-17 |
2023-08-12 |
Not clear |
| Seán T O'Dowd, Mustafa T Ardah, Per Johansson, Aleksey Lomakin, George B Benedek, Kinley A Roberts, Gemma Cummins, Omar M El Agnaf, Johan Svensson, Henrik Zetterberg, Timothy Lynch, Dominic M Wals. The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms. Journal of Alzheimer's disease : JAD. vol 33. issue 4. 2013-10-17. PMID:23034520. |
hence, the disparity between total-tau levels encountered in alzheimer's disease and other neurodegenerative conditions is not due to differential recognition of tau assembly forms or the extent of degeneration. |
2013-10-17 |
2023-08-12 |
Not clear |